Collectively, these data indicate that although both BPA and DHT can activate mutant AR and resultant cellular proliferation in prostate cancer cells, each agent induces a unique molecular signature, wherein genetic profiles induced by mitogenic doses of DHT or BPA showed both overlapping (e.g., PSA and ERβ) and divergent (e.g., FKBP5, WISP3) responses. The gene discussed is ESR2; the disease is prostate cancer.